Separately, HC Wainwright reaffirmed a buy rating and set a $3.00 target price on shares of Celsion Corp. in a report on Tuesday, July 12th.
Celsion Corp. (NASDAQ:CLSN) opened at 1.14 on Tuesday. The stock has a 50 day moving average price of $1.22 and a 200-day moving average price of $1.34. Celsion Corp. has a 12-month low of $1.04 and a 12-month high of $2.31. The firm’s market capitalization is $29.42 million.
Celsion Corp. (NASDAQ:CLSN) last posted its earnings results on Monday, August 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. Celsion Corp. had a negative net margin of 3,966.14% and a negative return on equity of 103.07%. On average, equities research analysts forecast that Celsion Corp. will post ($0.83) EPS for the current year.
A hedge fund recently raised its stake in Celsion Corp. stock. Sabby Management LLC boosted its position in shares of Celsion Corp. (NASDAQ:CLSN) by 7,986.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 1,519,365 shares of the company’s stock after buying an additional 1,500,576 shares during the period. Sabby Management LLC owned approximately 6.48% of Celsion Corp. worth $1,930,000 as of its most recent filing with the SEC. Institutional investors own 15.19% of the company’s stock.
Celsion Corp. Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corp. and related companies with MarketBeat.com's FREE daily email newsletter.